{"entity":{"id":"swog-s1418","kind":"trial","name":"SWOG S1418 / NRG BR006","aka":["S1418","NRG-BR006","SWOG S1418"],"tldr":"SWOG S1418 is the trial that will say whether a year of pembrolizumab after surgery, on its own, helps women whose triple-negative breast cancer survived pre-operative chemotherapy. It finished recruiting 1,195 patients and is due to report from 2026.","summary":"SWOG S1418/NRG BR006 (NCT02954874) randomised 1,195 patients with triple-negative breast cancer and residual invasive disease of at least 1 cm or positive lymph nodes (ypN1mi to ypN3) after neoadjuvant chemotherapy to one year of pembrolizumab or observation, with radiotherapy per standard of care; the primary endpoint is invasive disease-free survival, with fatigue and physical function as co-primary patient-reported endpoints. It opened in January 2017, before KEYNOTE-522 made neoadjuvant pembrolizumab standard, so it isolates the adjuvant contribution of pembrolizumab in a population that has not had it before surgery, a question KEYNOTE-522 could not answer. The registry lists primary completion in August 2026 and the trial as active, not recruiting; no results were indexed in September 2026. In England the matching NICE appraisal, pembrolizumab as adjuvant treatment after neoadjuvant chemotherapy (GID-TA11724), is awaiting development.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02954874","url":"https://clinicaltrials.gov/study/NCT02954874"}],"tags":[],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["swog"],"institutions":["nci"],"pathways":[],"terms":["rcb","efs","tnbc-residual-disease-decision"],"trials":["keynote-522","a-brave","impassion030"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Key facts: adjuvant pembrolizumab for one year versus observation after residual disease of 1 cm or more or node-positive disease following neoadjuvant chemotherapy; primary endpoint invasive disease-free survival; 1,195 enrolled; primary completion August 2026 (registry); no results in September 2026."],"nct":"NCT02954874","phase":"3","setting":"Triple-negative breast cancer with residual invasive disease of 1 cm or more, or positive lymph nodes, after neoadjuvant chemotherapy without immunotherapy: one year of adjuvant pembrolizumab versus observation, United States, Canada and Puerto Rico","sponsor":"National Cancer Institute (NCI), SWOG and NRG Oncology","enrolled":1195,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/swog-s1418/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/"},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"trial":[{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/"},{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"}]}}